Organisation paid for research Program year 2025 Source: CMS Open Payments

The Clinical Trials Network

Neither a doctor nor a teaching hospital

Research payments

$3,252,147

176 payments

Through program year 2025, The Clinical Trials Network is reported as receiving $3,252,147 in research payments, across 176 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$243,696	12
2024	Research	$2,251,995	113
2023	Research	$485,947	27
2022	Research	$141,324	12
2021	Research	$124,384	9
2020	Research	$4,800	3

Breakdown

Who paid Research payments · program years 2020–2025

CapsoVision, Inc. $1,679,484 45 payments
Roche TCRC, Inc. $705,287 56 payments
AstraZeneca UK Limited $290,479 6 payments
E.R. Squibb & Sons, L.L.C. $231,904 6 payments
Genentech, Inc. $168,132 19 payments
Braintree Laboratories, Inc. $64,657 19 payments
Celgene Corporation $54,828 2 payments
GlaxoSmithKline, LLC. $40,459 12 payments
Allergan Inc. $4,800 3 payments
Phathom Pharmaceuticals, Inc. $4,421 4 payments

Studies the money was for Research payments · program years 2020–2025

Cln-Cvi-5794 $1,679,484 45 payments
Phase 2 Study to Investigate Ro7200220 in Diabetic MacUlar Edema $411,847 27 payments
Oral Treatment of NPDR $293,440 29 payments
A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice $200,233 5 payments
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine $174,053 2 payments
Iamd Observational Study $133,780 17 payments
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $115,426 3 payments
A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $64,657 19 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $40,459 12 payments
Belvedere $34,352 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.